IGF-1Rの発現レベルは原発性・転移性の前立腺がん患者の腫瘍の大部分で上昇している[19]。IGF-1Rを介したシグナル伝達は、前立腺がん細胞がアンドロゲン非依存性へと進行した際の生存と成長に必要であることが示唆されている[20]。加えて、重症病態を模した不死化前立腺がん細胞は、IGF-1RのリガンドであるIGF-1による処理によって細胞の運動性が上昇する[21]。IGF受容体ファミリーのメンバーとそのリガンドは、イヌの乳腺腫瘍の発がんにも関与しているようである[22][23]。TCGA(英語版)(The Cancer Genome Atlas)のデータ解析からは、いくつかのがんのタイプでIGF-1Rの遺伝子が増幅していることが示されており、遺伝子増幅ががんにおけるIGF-1Rの過剰発現機構の1つである可能性がある[24]。
^“Insulin-like growth factors and their binding proteins: biological actions”. Endocrine Reviews16 (1): 3–34. (February 1995). doi:10.1210/edrv-16-1-3. PMID7758431.
^“Molecular and cellular aspects of the insulin-like growth factor I receptor”. Endocrine Reviews16 (2): 143–63. (April 1995). doi:10.1210/edrv-16-2-143. PMID7540132.
^“Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis”. Biochimica et Biophysica Acta1836 (2): 345–53. (December 2013). doi:10.1016/j.bbcan.2013.10.005. PMID24189571.
^“Insulin-like growth factor-1 receptor immunoreactive cells are selectively maintained in the paraventricular hypothalamus of calorically restricted mice”. International Journal of Developmental Neuroscience25 (1): 23–8. (February 2007). doi:10.1016/j.ijdevneu.2006.11.004. PMID17194562.
^“Age-dependent loss of insulin-like growth factor-1 receptor immunoreactive cells in the supraoptic hypothalamus is reduced in calorically restricted mice”. International Journal of Developmental Neuroscience24 (7): 431–6. (November 2006). doi:10.1016/j.ijdevneu.2006.08.008. PMID17034982.
^“Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease”. Cancer Research62 (10): 2942–50. (May 2002). PMID12019176.
^“Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model”. Cancer Research64 (23): 8620–9. (December 2004). doi:10.1158/0008-5472.CAN-04-2446. PMID15574769.
^“RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility”. Oncogene25 (16): 2285–96. (April 2006). doi:10.1038/sj.onc.1209260. PMID16314838.
^“Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer”. Veterinary and Comparative Oncology8 (4): 293–301. (December 2010). doi:10.1111/j.1476-5829.2009.00232.x. PMID21062411.
^“C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor”. The Journal of Biological Chemistry274 (9): 5422–8. (February 1999). doi:10.1074/jbc.274.9.5422. PMID10026153.
^ abc“Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis”. Cancer Research68 (14): 5669–77. (July 2008). doi:10.1158/0008-5472.CAN-07-6364. PMID18632619.
^“Association of insulin-like growth factor 1 receptor with EHD1 and SNAP29”. The Journal of Biological Chemistry276 (35): 33054–60. (August 2001). doi:10.1074/jbc.M009913200. PMID11423532.
^ abc“Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10”. Molecular Endocrinology10 (6): 631–41. (June 1996). doi:10.1210/mend.10.6.8776723. PMID8776723.
^“Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains”. The Journal of Biological Chemistry273 (12): 6860–7. (March 1998). doi:10.1074/jbc.273.12.6860. PMID9506989.
^“Grb10: A new substrate of the insulin-like growth factor I receptor”. Cancer Research56 (14): 3165–7. (July 1996). PMID8764099.
^ ab“Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system”. The Journal of Biological Chemistry270 (40): 23456–60. (October 1995). doi:10.1074/jbc.270.40.23456. PMID7559507.
^ ab“Localization of the insulin-like growth factor I receptor binding sites for the SH2 domain proteins p85, Syp, and GTPase activating protein”. The Journal of Biological Chemistry270 (32): 19151–7. (August 1995). doi:10.1074/jbc.270.32.19151. PMID7642582.
^“Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor”. The Journal of Biological Chemistry273 (37): 24095–101. (September 1998). doi:10.1074/jbc.273.37.24095. PMID9727029.
^“14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner”. The Journal of Biological Chemistry272 (17): 11663–9. (April 1997). doi:10.1074/jbc.272.17.11663. PMID9111084.
“IGF-I: a mitogen also involved in differentiation processes in mammalian cells”. The International Journal of Biochemistry & Cell Biology28 (5): 499–510. (May 1996). doi:10.1016/1357-2725(95)00168-9. PMID8697095.
“Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology”. Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology121 (1): 19–26. (September 1998). doi:10.1016/S0305-0491(98)10106-2. PMID9972281.
“The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance”. Cancer Metastasis Reviews22 (4): 327–36. (December 2003). doi:10.1023/A:1023720928680. PMID12884909.
“Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor”. Growth Factors22 (2): 89–95. (June 2004). doi:10.1080/08977190410001700998. PMID15253384.
“Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer”. Journal of Experimental & Clinical Cancer Research23 (3): 385–94. (September 2004). PMID15595626.
“Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer”. Molecular and Cellular Endocrinology252 (1–2): 241–6. (June 2006). doi:10.1016/j.mce.2006.03.018. PMID16647191.